Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity

被引:57
作者
Mayo, KH
Dings, RPM
Flader, C
Nesmelova, I
Hargittai, B
van der Schaft, DWJ
van Eijk, LI
Walek, D
Haseman, J
Hoye, TR
Griffioen, AW
机构
[1] Univ Minnesota, Hlth Sci Ctr, Dept Biochem, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Mol Biol & Biophys, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA
[4] Univ Hosp Maastricht, Dept Pathol, Res Inst Growth & Dev, Angiogenesis Lab, NL-6202 AZ Maastricht, Netherlands
[5] Univ Hosp Maastricht, Dept Internal Med, Res Inst Growth & Dev, Angiogenesis Lab, NL-6202 AZ Maastricht, Netherlands
关键词
D O I
10.1074/jbc.M308608200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Based on structure-activity relationships of the angiostatic beta-sheet-forming peptide anginex, we have designed a mimetic, 6DBF7, which inhibits angiogenesis and tumor growth in mice. 6DBF7 is composed of a beta-sheet-inducing dibenzofuran (DBF)-turn mimetic and two short key amino acid sequences from anginex. This novel antiangiogenic molecule is more effective in vivo than parent anginex. In a mouse xenograft model for ovarian carcinoma, 6DBF7 is observed to reduce tumor growth by up to 80%. It is suggested that the activity is based on antiangiogenesis, because in vitro tube formation is inhibited, and because treatment of tumor-bearing mice led to a significant reduction in microvessel density within the tumor. This partial peptide mimetic is the first endothelial cell-specific molecule designed as a substitute for an angiostatic inhibitory peptide.
引用
收藏
页码:45746 / 45752
页数:7
相关论文
共 45 条
[21]  
KING DS, 1990, INT J PEPT PROT RES, V36, P255
[22]   Tissue-type plasminogen activator is a multiligand cross-β structure receptor [J].
Kranenburg, O ;
Bouma, B ;
Kroon-Batenburg, LMJ ;
Reijerkerk, A ;
Wu, YP ;
Voest, EE ;
Gebbink, MFBG .
CURRENT BIOLOGY, 2002, 12 (21) :1833-1839
[23]   THE IP-10 CHEMOKINE BINDS TO A SPECIFIC CELL-SURFACE HEPARAN-SULFATE SITE SHARED WITH PLATELET FACTOR-4 AND INHIBITS ENDOTHELIAL-CELL PROLIFERATION [J].
LUSTER, AD ;
GREENBERG, SM ;
LEDER, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (01) :219-231
[24]   Endostatin binds tropomyosin - A potential modulator of the antitumor activity of endostatin [J].
MacDonald, NJ ;
Shivers, WY ;
Narum, DL ;
Plum, SM ;
Wingard, JN ;
Fuhrmann, SR ;
Liang, H ;
Holland-Linn, J ;
Chen, DHT ;
Sim, BKL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (27) :25190-25196
[25]   Designed β-sheet peptides that inhibit proliferation and induce apoptosis in endothelial cells [J].
Mayo K.H. ;
Van Der Schaft D.W.J. ;
Griffioen A.W. .
Angiogenesis, 2001, 4 (1) :45-51
[26]   NMR SOLUTION STRUCTURE OF THE 32-KDA PLATELET FACTOR-4 ELR-MOTIF N-TERMINAL CHIMERA - A SYMMETRICAL TETRAMER [J].
MAYO, KH ;
ROONGTA, V ;
ILYINA, E ;
MILIUS, R ;
BARKER, S ;
QUINLAN, C ;
LAROSA, G ;
DALY, TJ .
BIOCHEMISTRY, 1995, 34 (36) :11399-11409
[27]   Rocking the foundations of solid tumor growth by attacking the tumor's blood supply [J].
Molema, G ;
Griffioen, AW .
IMMUNOLOGY TODAY, 1998, 19 (09) :392-394
[28]   Angiostatin binds ATP synthase on the surface of human endothelial cells [J].
Moser, TL ;
Stack, MS ;
Asplin, I ;
Enghild, JJ ;
Hojrup, P ;
Everitt, L ;
Hubchak, S ;
Schnaper, HW ;
Pizzo, SV .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (06) :2811-2816
[29]   ANGIOSTATIN - A NOVEL ANGIOGENESIS INHIBITOR THAT MEDIATES THE SUPPRESSION OF METASTASES BY A LEWIS LUNG-CARCINOMA [J].
OREILLY, MS ;
HOLMGREN, L ;
SHING, Y ;
CHEN, C ;
ROSENTHAL, RA ;
MOSES, M ;
LANE, WS ;
CAO, YH ;
SAGE, EH ;
FOLKMAN, J .
CELL, 1994, 79 (02) :315-328
[30]   Endostatin: An endogenous inhibitor of angiogenesis and tumor growth [J].
OReilly, MS ;
Boehm, T ;
Shing, Y ;
Fukai, N ;
Vasios, G ;
Lane, WS ;
Flynn, E ;
Birkhead, JR ;
Olsen, BR ;
Folkman, J .
CELL, 1997, 88 (02) :277-285